Menu
Your Cart

Apostle MiniMax High Efficiency Magnetic Nanoparticles (25.8 mL, Kit Component)

Apostle MiniMax High Efficiency Magnetic Nanoparticles (25.8 mL, Kit Component)
Secured Shopping
Best security features
Apostle MiniMax High Efficiency Magnetic Nanoparticles (25.8 mL, Kit Component)

(Kit Component) Apostle MiniMax High Efficiency Magnetic Nanoparticles (25.8 mL)

is a component of

Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit

  • Powered by Apostle MiniMax technology, Apostle MiniMax High Efficiency cfDNA Isolation Kit is an excellent tool for the isolation of ultra-low concentration cell free DNA (cfDNA). 
  • The superb performance of Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit has been extensively validated.  Please review the examples of publications and performance data at: https://apostlebio.com/index.php?route=information/information&information_id=15 
  • Configuration: 25.8 mL/bottle.
  • Cat #: A17622-MN-1536.



$1,732.52
Add to Cart
Ask Question
Add to Wish List Compare this Product
Tags: Kit Component , cfDNA Isolation Kit
Quickview
Apostle MiniMax High Efficiency Magnetic Nanoparticles (5mL)
Apostle MiniMax High Efficiency Magnetic Nanoparticles (5mL)
Apostle MiniMax technology ensures precise capture and separation of DNA, RNA, and other biomolecules. This is achieved through Apostle’s novel propri..
$864.00
Add to Cart
Add to Wish List Compare this Product
A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.